874-36-2

Basic information

• Product Name: 2,1,3-BENZOXADIAZOL-5-AMINE
• Synonyms: 2,1,3-BENZOXADIAZOL-5-AMINE;Benzo[c][1,2,5]oxadiazol-5-aMine;2,1,3-benzoxadiazol-6-amine;Benzo[1,2,5]oxadiazol-5-ylamine;benzofurazan-5-ylamine
• CAS NO: 874-36-2
• Molecular Formula: C₆H₅N₃O
• Molecular Weight: 135.13
• Mol File: 874-36-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 290.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 0.92±0.10(Predicted)
• CAS DataBase Reference: 2,1,3-BENZOXADIAZOL-5-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,1,3-BENZOXADIAZOL-5-AMINE(874-36-2)
• EPA Substance Registry System: 2,1,3-BENZOXADIAZOL-5-AMINE(874-36-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 874-36-2(Hazardous Substances Data)

Usage

General Description

2,1,3-Benzoxadiazol-5-amine, also known as BODIPY-FL, is a fluorescent dye molecule commonly used in various biochemical and cell biological applications. It belongs to the family of BODIPY (boron-dipyrromethene) dyes and is characterized by its high fluorescence quantum yield, good photostability, and excellent solubility in organic solvents. BODIPY-FL is often used as a fluorescent label in nucleic acid, protein, and lipid labeling, as well as in studying cellular and subcellular structures and functions. Its strong fluorescence emission in the green spectral range makes it a valuable tool in fluorescence microscopy, flow cytometry, and other imaging techniques, enabling the study of various biological processes and interactions at the molecular level.

Upstream product

• 36387-84-5 4-bromo-9-oxido-8-oxa-7,9-diazabicyclo[4.3.0]nona-1⁽⁹⁾,2,4,6-tetraene 
• 875-51-4 4-Bromo-2-nitroaniline 
• 51376-06-8 5-bromo-benzo[1,2,5]oxadiazole 
• 19155-88-5 benzo[c][1,2,5]oxadiazole-5-carboxylic acid 
• 18772-11-7 5-nitro-2,1,3-benzoxadiazole 

Downstream Products

• 1026305-49-6 N-[2-(2,1,3-benzoxadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.